Latigo Biotherapeutics (LTGO) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$27.59

Estimate

-$0.66

Surprise

-4048.9%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Latigo Biotherapeutics (LTGO) reported a wider loss than forecast — diluted EPS of -$27.59 against the -$0.66 estimate (a 4048.9% shortfall).

• Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY — benzinga, 2026-09-03
• Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36 — benzinga, 2026-09-01
• Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 — benzinga, 2026-09-01

TrendMatrix currently rates LTGO Sell at 5.3/10; no pre/post engine snapshot brackets this report.

0 of the last 1 quarters beat the estimate; this quarter's -4048.9% surprise compares with a -4048.9% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$22.15

Price target

$44.41

Stop

$20.60

Upside to target

+100.5%

Reward-to-risk

6.7:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.47B

P/E (fwd)

-10.6

52-week range

$17.22–$25.93

Off 52-week high

14.6%

RSI (14)

49

Volume vs avg

0.87×

Score today

5.3/10